[CAS NO. 878385-84-3] AZD-5069
PRODUCTS SPECIFICATIONS [878385-84-3]
DESCRIPTION [878385-84-3]
Overview
| MDL | MFCD19443645 |
|---|---|
| Molecular Weight | 476.52 |
| Molecular Formula | C18H22F2N4O5S2 |
| SMILES | O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O |
1 Publications Citing Use of MCE
Summary
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
IC50 & Target
|
125 I-IL-8-CXCR2 |
In Vitro
AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [ 125 I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GROα-induced Ca 2+ flux in human neutrophils loaded with fluo-3 dye [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02583477 | AstraZeneca |
Metastatic Pancreatic Ductal Adenocarcinoma
|
March 25, 2016 | Phase 1|Phase 2 |
| NCT01100047 | AstraZeneca |
Healthy
|
May 2010 | Phase 1 |
| NCT01962935 | AstraZeneca |
Chronic Obstructive Pulmonary Disease (COPD).
|
November 2013 | Phase 1 |
| NCT01890148 | AstraZeneca |
Asthma
|
March 2014 | Phase 1 |
| NCT01255592 | AstraZeneca |
Bronchiectasis|Lung Disease|Respiratory Diseases
|
February 2011 | Phase 2 |
| NCT03177187 | Institute of Cancer Research, United Kingdom|Astellas Pharma Inc|AstraZeneca|Prostate Cancer UK |
Metastatic Castration Resistant Prostate Cancer
|
November 13, 2017 | Phase 1|Phase 2 |
| NCT00953888 | AstraZeneca |
Healthy
|
July 2009 | Phase 1 |
| NCT01083238 | AstraZeneca|Quintiles, Inc. |
Chronic Obstructive Pulmonary Disease
|
February 2010 | Phase 1 |
| NCT01735240 | AstraZeneca |
Asthma,|Pharmacokinetics,|Cmax,|Tmax,|λz,|AUC,|Ketoconazole,|Metabolite
|
December 2012 | Phase 1 |
| NCT01332903 | AstraZeneca |
Healthy
|
May 2011 | Phase 1 |
| NCT02499328 | AstraZeneca|MedImmune LLC |
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
|
August 6, 2015 | Phase 1|Phase 2 |
| NCT01051505 | AstraZeneca |
Healthy
|
January 2010 | Phase 1 |
| NCT01480739 | AstraZeneca |
Chemokine Receptor 2 (CXCR2) Antagonist
|
December 2011 | Phase 1 |
| NCT01233232 | AstraZeneca |
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)|Laymen Terminology Chronic Bronchitis and Emphysema
|
November 2010 | Phase 2 |
| NCT01704495 | AstraZeneca |
Asthma
|
November 2012 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 90 mg/mL ( 188.87 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0985 mL | 10.4927 mL | 20.9855 mL |
| 5 mM | 0.4197 mL | 2.0985 mL | 4.1971 mL |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0985 mL |
-
1.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 12.5 mg/mL (26.23 mM); Suspended solution; Need ultrasonic
-
2.
-
3.
-
4.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
-
5.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution